|Chemical and physical data|
|Molar mass||397.409 g/mol g·mol−1|
|3D model (JSmol)|
CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects. A number of related compounds have been developed with similar properties.
- Ohta H, et al. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. Bioorganic and Medicinal Chemistry. 2008 Feb 1;16(3):1111-24. PMID 18006322
- Hiroshi Ohta; Tomoko Ishizaka; Makoto Tatsuzuki; Mitsukane Yoshinaga; Izumi Iida; Yasumitsu Tomishima; Yoshihisa Toda; Shuji Saito (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–6304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|